Direct oral anticoagulants (DOACs) may be good alternatives to low molecular weight
heparin (LMWH) or vitamin K antagonists (VKA) for treatment of cancer associated …

Cancer-associated thrombosis (CAT) is a common complication in patients with malignancy.
Although direct oral anticoagulants (DOACs) have emerged as a treatment option for CAT …

Simple Summary Direct-acting oral anticoagulants are becoming popular therapeutic option
in patients with cancer. We investigated the available literature in order to try to sum up the …

Anticoagulation for cancer-associated venous thromboembolism (VTE) can be challenging
due to complications—including bleeding and potential drug–drug interactions with …

Background Recently, direct oral anticoagulants (DOACs) have been included in guidelines
for the treatment of cancer-associated thrombosis (CAT) to be extended to suitable cancer …

Background: Venous thromboembolism (VTE) is a common complication in patients with
cancer. Direct oral anticoagulants (DOACs) have been proved to be effective on …

The use of anticoagulants in patients with cancer is challenging as several co-morbidities
modifying pharmacokinetic (PK) parameters and significant drug-drug interactions with …

Venous thromboembolism (VTE) is frequently encountered in patients with cancer. Cancer
patients have an increased risk of VTE during the entire course of their disease, but this risk …

Background Current clinical practice guidelines all recommend the use of therapeutic doses
of low molecular weight heparins (LMWH) for the initial and long-term treatment of cancer …

Introduction Real-world evidence on the effects of direct oral anticoagulants (DOACs) in
patients with cancer associated venous thromboembolism (VTE) is limited. Thus, our …